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ABSTRACT 
 
Gastric cancer is the fourth most commonly diagnosed cancer and the second leading 
cause of cancer death worldwide. HER2 (human epidermal growth factor receptor 2), 
an oncogene of the HER family of growth factors has been shown to be overexpressed 
in gastric cancer. Trastuzumab is a monoclonal antibody targeting HER2, which 
demonstrated to significantly prolong overall survival in association with standard 
chemotherapy in this patients in the ToGA (Trastuzumab for GAstric Cancer) trial. 
These data contributed for the approval of trastuzumab in combination therapy in the 
treatment of metastatic adenocarcinoma of the stomach or gastro-esophageal junction 
by various international authorities. Aiming to address the particular issues of the 
patients diagnosed and treated at Instituto Português de Oncologia do Porto (IPOP), a 
retrospective cohort study was designed in order to estimate the proportion of patients 
eligible for trastuzumab therapy at this particular centre.  
Ninety-eight patients admitted during 2005 and 2006 at IPOP with metastatic or locally 
advanced gastric or GEJ intestinal-type adenocarcinoma were included and 
characterized according to clinicopathological variables. HER2-status was determined 
by immunohistochemistry. Ambiguous cases were analyzed by silver in-situ 
hybridization.  
Overall survival in the study sample was 36 months [24-48], with a disease-free 
survival of  12 months [8-16]. Overall positivity for HER2 was 16.3%. HER2 correlated 
significantly with pathological stage, N-status and N-ratio (p < 0.05). Overall survival in 
HER2- patients was 43 vs. 19 months in HER2 positive patients (p=0.032). 
Our data suggest an important role for HER2 as prognostic factor. The methods used 
for HER2 assessment proved to be efficient. Anti-HER2 therapeutics in gastric cancer 
seem to have a role the adjuvant setting and in patients with locally advanced disease.  
 
Key-words (MESH): stomach neoplasms, esophageal neoplasms, trastuzumab, 
ERBB2, amplification, immunohistochemistry, in situ hybridisation 
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RESUMO 
O cancro gástrico é a 4ª neoplasia mais frequentemente diagnosticada e a 2ª causa de 
morte por cancro no mundo. O oncogene HER2 (human epidermal growth factor 
receptor 2), pertencente à família HER dos factores de crescimento, encontra-se 
sobre-expresso no cancro gástrico. O trastuzumab é um anticorpo monoclonal dirigido 
ao HER2, que demonstrou prolongar a sobrevivência em associação com 
quimioterapia nos doentes que sobre-expressam o HER2, no ensaio clínico ToGA 
(Trastuzumab for GAstric Cancer). Estes dados contribuíram para a aprovação do 
trastuzumab em terapêutica combinada no tratamento do adenocarcinoma metastático 
do estômago e da junção esófago-gástrica (JEG). No intuito de perceber a realidade 
existente no Instituto Português de Oncologia do Porto (IPOP), foi desenhado um 
estudo de coorte retrospectivo, com o objectivo primário de estimar a proporção de 
doentes potencialmente elegíveis para terapêutica com trastuzumab.  
Noventa e oito doentes admitidos durante 2005 e 2006 com o diagnostico de 
adenocarcinoma do tipo intestinal do estômago ou JEG foram incluídos e analizados 
quanto a variáveis clinicopatológicas. O status HER2 foi determinado por 
imunohistoquímica, tendo os casos ambíguos sido analisados por hibridização in situ 
com prata.  
A sobrevivência global foi de 36 meses [24-48], com uma sobrevivência livre de 
doença de 12 meses [8-16]. A positividade global para o HER2 foi de 16,3%. O status 
HER2 correlaciona-se significativamente com o estádio patológico, positividade 
ganglionar e razão de gânglios metastizados / gânglios excisados (p < 0.05). A 
sobrevivência global em doentes HER2- foi de 43 vs. 19 meses em doentes HER2+ 
(p=0.032). 
Os dados sugerem um papel importante para o HER2 como factor de prognóstico. Os 
métodos utilizados para a determinação do status HER2 demonstraram ser eficazes. A 
terapêutica HER2 no cancro gástrico parece ter um papel no contexto adjuvante e em 
doentes com doença localmente avançada.  
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"É preciso fazer um esforço contínuo para amar o presente. Viver pelo 
passado, pelo que se fez, pelo que se conseguiu, é o mesmo que alimentar 
uma fome premente com banquetes de outrora." 
Miguel Torga 
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INTRODUCTION 
 
Epidemiology of Gastric Cancer 
 
Gastric cancer is the fourth most commonly diagnosed cancer and the second leading 
cause of cancer death worldwide, with an estimated 990.000 new cases and 738.000 
cancer deaths in 2008 (1). In the northern region of Portugal, gastric cancer has an 
incidence rate of about 47.4/100.000 person-years in men and 28/100.000 person-
years in women (2). Incidence rates show considerable geographic variation, varying 
from 3.3 per 100.000 in men and 2.0 in women in Egypt to 65.9 in men and 25.9 in 
women in Korea. Highest rates are found in Asian and South American countries. 
These large regional variations possibly reflect different prevalences of Helicobacter 
pylori infection, which is responsible for more than 60% of gastric cancer globally (3). 
About 85% of gastric cancers are adenocarcinomas, with 15% comprised of 
lymphomas, gastrointestinal stromal tumors (GIST) and leiomyosarcomas. Gastric 
adenocarcinomas can be subdivided into diffuse and intestinal types based on the 
Lauren classification, which constitute pathological entities with distinct epidemiological 
and prognostic features (4). In diffuse type gastric adenocarcinoma cell cohesion is 
absent; they occur throughout the entire stomach and more often in younger patients 
than in intestinal type adenocarcinoma and carry a worse prognosis. Intestinal type 
gastric adenocarcinoma presents cohesive cells arranged in glandlike structures; they 
occur more commonly in the antrum and lesser curvature of the stomach (4-6). 
Different etiologic factors seem to be involved, as incidence of diffuse type is similar in 
most populations while intestinal type predominates in high risk regions. A decrease in 
gastric cancer incidence in the United States in the last 70 years has been mainly 
observed for the intestinal type, associated with Helicobacter pylori infection and 
therefore reflecting improved sanitary conditions and food conservation methods, 
including refrigeration; on the other hand, the incidence of diffuse type gastric cancer 
has remained constant over time and seems to be increasing recently, both in Western 
and Eastern parts of the world (7-9). 
Tumors at the junction of the esophagus with the stomach are oftentimes of either 
gastric or esophageal origin and are therefore referred as gastroesophageal junction 
(GEJ) cancers. Although the incidence and mortality of gastric cancer are globally 
decreasing, the incidence of GEJ cancer is increasing in Europe and the United States 
(10, 11).  This increase is thought to reflect an increase in gastroesophageal reflux 
disease associated with the increasing prevalence of obesity in these countries. In the 
last three decades, a tendency towards more proximal located gastric cancer (cardia 
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vs. corpus and pylorus) is emerging, probably explained by a parallel increase of 
Barrett’s esophagus and the decline in Helicobacter pylori infection (10, 12).  
In western countries, 50 - 80% of patients present with inoperable advanced or 
metastatic disease, which in combination with patient co-morbidities, age (the majority 
of patients is > 65 years old) and the relative chemoresistance of the disease 
contributes to poor overall survival (OS). A prognostic index for locally advanced and 
metastatic esophago-gastric cancer (the Royal Marsden Hospital Prognostic Index) 
was initially published in 2004, with data supporting its validity presented in 2009 (13, 
14). Four independent poor prognostic factors are taken in consideration: performance 
status ≥ 2, liver metastasis, peritoneal metastasis, and serum alkaline phosphatase ≥ 
100 U/L. Patients are subdivided into good (no risk factor), moderate (1 or 2 risk 
factors), and poor (3 or 4 risk factors) risk groups. Applying this index to the data of the 
REAL-2 study (described below) resulted in statistically significant differences between 
the 3 risk groups in terms of median survival and 1-year survival rates (median survival 
times for good, moderate, and poor risk groups were 12.7, 8.6, 4.3 months 
respectively; 1-year survival rates were 52.4%, 33.1% and 13.7% respectively (14). 
Two-thirds of patients amenable to curative surgical resection will have recurrence 
within 2 years (15-17). The late presentation contributes to the grim prognosis 
associated with gastric cancer, with 5-year survival rate for metastatic gastric cancer 
being estimated at 5-20% and median survival times ranging from 7 to 10 months (18, 
19). The survival rates of patients with resectable disease ranges from 10-30% (20). 
Combination chemotherapy has been shown to improve overall survival in comparison 
with single-agent chemotherapy or best supportive care (21). Current management 
typically consists of ﬂuoropyrimidine and platinum-based combinations with or without a 
third drug (usually docetaxel or epirubicin) (22). However, data available have been 
conflicting when it comes to evaluate the clinical outcome with different treatment 
strategies, which can explain the lack of global consensus for adjuvant chemotherapy 
(23, 24). Considering the poor prognosis of advanced gastric or GEJ cancer, new 
therapeutic regimens with acceptable toxicity have been actively pursued. 
Pathology of gastric cancer 
Sporadic intestinal type gastric adenocarcinoma is thought to arise in a multi-step 
process of intestinal metaplasia – dysplasia – carcinoma, involving mutations or 
deregulation of genes regulating key events in the cancerization process such as 
apoptosis, cell cycle regulation, proliferation and metabolism, in a similar fashion of the 
progression of colon adenomas to carcinoma (25). Therefore, accumulation of 
molecular genetic alterations involving activation of oncogenes and inactivation of 
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tumor suppressor genes are likely involved in the process of carcinogenesis. Other 
implicated genes include p53, CHD1, SMAD4, FHIT and CDKN2A. On the other hand, 
no precursor cells have been clearly identified in diffuse type gastric adenocarcinoma, 
but aberrations in the FGFR2/ErbB3/PI3 kinase pathway are frequent in this kind of 
neoplasia (26-29). 
Information on the specific pathways involved is scarce; however, HER2 has been 
shown to be overexpressed/amplified in gastric cancer and correlation between HER2 
expression and intestinal type gastric cancer has been reported (30). HER2 is a 
member of the epidermal growth factor receptor (EGFR) family of growth factors, with 
intrinsic protein tyrosine kinase activity and its increased activity is an assumed 
mechanism underlying cell transformation. The EGFR family includes four structurally 
related members, ErbB1 (HER1), also known as EGFR, ErbB2 (HER2), ErbB3 (HER3) 
and ErbB4 (HER4) (31). These receptors are known to be activated by homo- or 
heterodimerization induced by ligands. However, no ligand has as far been identified 
for HER2, which is therefore an orphan receptor. It is believed that the receptor 
homodimerizes independently of a ligand or heterodimerizes with another ligand-bound 
member of the EGFR family for activation (32). Ligand-independent homodimerization 
will occur in the setting of HER2 overexpression. The HER2 protein, a 185 kDa protein 
(p185) encoded by a gene located on chromosome 17q21 is a transmembrane tyrosine 
kinase receptor with an extracellular ligand-binding domain; a short transmembrane 
domain and an intracellular domain with kinase activity (see Fig. 1).  
 
 
Figure 1 
The HER2 receptor 
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As aforementioned, the receptor is activated through homodimerization or 
heterodimerization, leading to a cascade of events that involves autophosphorilation 
and activation of the tyrosine kinase domain, Ras/Raf/mitogen-activated protein kinase 
(MAPK) pathway, phospholipase C-γ (PLC γ) and phosphatidylinositol-3-kinase 
(PI3K)/Akt/mammalian target of rapamycin (mTOR) (see Fig.2).  
 
 
Figure 2 
HER2-activated pathways 
 
Furthermore, HER2 receptors have been found in nuclear localization, where they can 
act as transcription factors for cycline D1 and p53 (33, 34). Therefore, HER2 (also 
known as c-erbB-2/neu) is an oncogene that is involved in the regulation of cell 
proliferation, differentiation, motility and apoptosis (35-39). Despite being an orphan 
receptor it is known that, if overexpressed, the receptor becomes a preferential binding 
partner for other family members, leading to ligand-independent hetero- and 
homodimerization. This ligand-independent dimerization is better understood in the 
light of crystal structure studies, which show fixed conformations resembling a ligand 
activated state and interaction with other family members in the absence of any ligand 
and therefore activating the mentioned oncogenic pathways (27, 40-43). Heterodimers 
of HER2 with other members of the HER family, particularly with HER3, are the most 
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mitogenic dimers and HER2 increases the affinity of EGFR, HER3 and HER4 to their 
own ligands (32, 44-46). 
Understanding the molecular structure of HER2 has allowed integrating the 
mechanisms through which the receptor can be approached as a therapeutic target 
(see Figs. 1 and 3).  
 
 
Figure 3 
HER2 ultrastructure 
 
The extracellular domain can be subdivided into four subdomains. Subdomains II and 
IV are involved in the process of dimerization and are the binding sites for pertuzumab 
and trastuzumab respectively, two of the most well studied HER2 inhibitors, whereas 
subdomains I and III are binding sites of potential ligands. Crystallographic data 
confirm that most receptors exist in an open configuration, where subdomains I and III 
associate to leave the dimerization arm protruded outside of subdomains II and IV. This 
might explain the role of HER2 as a preferred dimerization partner among the HER 
family. However, interesting data suggests that there is no lack of autoinhibitory 
interdomain interactions in HER2, as these are maintained and even extended when 
compared to EGFR. Some authors therefore suggest that HER2 signalling may be 
regulated by ligands that we do not know yet, just as in EGFR (26, 47). The 
transmembrane domain of HER2 plays an important role in the process of dimerization 
and oncogenic mutations in this region are known. At last, the intracellular domain 
contains the active enzyme site and activates different downstream pathways by 
phosphorylation (42, 48-50).  
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Treatment of gastric cancer 
Surgery constitutes a fundamental modality in treatment of resectable gastric cancer, 
with endoscopic submucosal dissection constituting a valid alternative to surgery in 
early gastric cancer (51). However, the optimal extent of lymph node dissection is a 
matter of debate, with different strategies applied in the western and eastern world, 
particularly Japan (27). Japanese practice advocates a D2 resection (en-bloc resection 
of perigastric and celiac axis nodes). Even with radical node dissection, survival 
remains poor, with 5-year survival rates typically < 50% for stage II disease with 
surgery alone (52). In a Dutch trial comparing D1 vs. D2 node dissection, 15-year 
survival was reported to be 33% for stage II and 19% for stage IIIA disease (53). While 
D2 dissection was associated with lower recurrence of the disease, higher surgical 
mortality and complication rate was observed and the authors found no difference in 
OS. Likewise, D2 resection + para-aortic nodal dissection seems not to improve OS or 
relapse-free survival; however a recent systematic review found no increase in post-
operative mortality with this technique, favouring D2 resection (53-56). Although 
surgery constitutes the only potentially curative procedure, most patients eventually 
recur in regional or distant sites, even after radical resection as mentioned above. 
Outcomes of operable cancer have improved since the introduction of multimodality 
therapies in the neoadjuvant/adjuvant setting (57).  
In 1999, Nakajima et al. presented the results of a phase III clinical trial of adjuvant 
chemotherapy after curative gastrectomy in macroscopically serosa-negative gastric 
cancer. A total of 579 patients were enrolled in the study, randomly allocated for 
adjuvant chemotherapy with mitomycin +5-fluorouracil (5-FU) for 3 weeks past surgery 
and uracil + tegafur for 18 months. No significant difference in survival between the 
groups was found (OS 82.9% in control group vs. 85.8% in treated patients) (58).   
Adjuvant chemoradiation has been shown to improve OS compared to surgery alone 
(59), but in the ARTIST (Adjuvant Chemoradiation Therapy in Stomach Cancer) trial, 
which compared adjuvant chemotherapy with adjuvant chemoradiation after D2 
resection, the addition of radiotherapy to chemotherapy with capecitabine + cisplatin 
did not significantly reduce recurrence after curative resection and D2 lymph node 
dissection (60).  
Perioperative chemotherapy was investigated by the MAGIC (Medical Research 
Council Adjuvant Gastric Infusional Chemotherapy) trial, where patients were treated 
with 3 cycles of 5-FU + cisplatin + epirubicin before and after radical surgery 
experienced a significant improvement in 5-year OS (23% vs. 36.3%), higher likelihood 
of progression-free survival (PFS), higher rate of curative surgery, reduced tumor size 
and less advanced nodal disease in comparison with the surgery-only group (27, 60, 
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61). In the French FNLCC Accord07-FFCD 9703 study, R0 resection rate after 
neoadjuvant therapy (cisplatin + 5-FU) was improved compared to surgical resection 
alone (84% vs. 73%, p = 0.04). Gain in the 5 year-DFS rate was 13% (34% vs. 21%, p 
= 0.0033) and in the 5- year OS rate was 38% vs. 24% (p = 0.021), favouring 
neoadjuvant chemotherapy (62). 
In another trial, adjuvant oral fluoropyrimidine monotherapy (with S-1) showed 
promising results, with 3-year OS rates of 80.1% in the chemotherapy group and 
70.1% in the surgery-only group (63). The potential of adjuvant chemotherapy was 
addressed by a metanalysis with data from 3838 patients, demonstrating a median OS 
of 7.8 years following adjuvant chemotherapy vs. 4.9 years following surgery alone, 
with the authors concluding that adjuvant 5-FU-based chemotherapy is associated with 
improvement in OS and is therefore recommended for patients who have not received 
perioperative treatments after gastric cancer resection (24). 
In metastatic gastric cancer, combination chemotherapy improves OS in comparison 
with single-agent chemotherapy or best supportive care (21). Objective response rates 
are estimated as 10 – 30% for single-agent therapy and 30 – 60% for combination 
therapy (64, 65). Current management typically consists of ﬂuoropyrimidine-based and 
platinum-based combinations with or without a third drug (usually docetaxel or 
epirubicin) (22). In a meta-analysis comprising 13 randomized trials, drug regimens 
containing 5-FU, anthracyclines and cisplatin achieved superior survival results 
compared to cisplatin + 5-FU or antracycline + 5-FU combinations; furthermore, 
regimens including irinotecan demonstrated a non-significant trend towards better 
survival (66). 
ECF (epirubicin + cisplatin + 5-FU) demonstrated response rates of 42.4%, with 
median survival of 9.4 months. MCF (mitomycin + cisplatin + 5-FU) had equivalent 
efficacy, but quality of life was superior with ECF (67). In the REAL-2 (Randomized 
ECF for Advanced and Locally Advanced Esophagogastric Cancer 2) trial conducted 
by Cunningham et al., 1002 patients were randomly assigned to receive triplet therapy 
with epirubicin and cisplatin + either 5-FU (ECF) or capecitabine (ECX) or triplet 
therapy with epirubicin and oxaliplatin + either 5-FU (EOF) or capecitabine (EOX). It 
demonstrated OSs between 9.3 and 11.2 months (with epirubicin + oxaliplatin + 
capecitabine). Toxic side-effects of capecitabine and 5-FU were comparable. 
Compared with cisplatin, oxaliplatin was associated with lower incidences of grade 3 or 
4 neutropenia, alopecia, renal toxicity, and thromboembolism but with higher 
incidences of grade 3 or 4 diarrhea and neuropathy (22, 68). Similar values were found 
in a recent single-center trial with an overall response rate of 51.1% and median OS of 
10.4 months (69). A median OS of 9.2 months was reported by Van Cutsem et al. in a 
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phase III clinical trial with patients receiving a combination therapy of docetaxel + 
cisplatin + 5-FU (vs. 8.6 months with cisplatin + 5-FU, p = 0.02) (70). OSs of 10.5 and 
10.7 months were reported in phase III trials with capecitabine + cisplatine and 5-FU + 
leucovirin + oxiplatin respectively (70-72). Irinotecan showed promising results as 2nd 
line therapy in metastatic gastric or GEJ cancer. In a phase III trial involving 40 
patients, irinotecan 250mg/m2 every 3 weeks was compared to best supportive care. 
Stable disease was found in 58% of patients; median survival in the irinotecan arm was 
of 123 days and 72.5 days in the best supportive care arm (73). The SPIRITS trial, a 
phase III trial which enrolled 305 patients, compared S-1 + cisplatin vs. S-1 alone in 
chemotherapy-naïve patients with advanced gastric cancer. Median OS was longer in 
patients assigned to S-1 + cisplatin (13 months) than in those assigned to S-1 alone 
(11 months). PFS was also significantly longer in patients assigned to S-1 + cisplatin 
than in those assigned to S-1 alone (median PFS of 6 months vs 4 months) (74).  
However, taken together, data available have been conflicting when it comes to 
evaluate the clinical outcome with different treatment strategies, which can explain the 
lack of global consensus for the choice of chemotherapy regimens (21, 23, 24). Even if 
adenocarcinomas of the GEJ have different clinicopathologic features as compared 
with distal gastric cancers, the chemotherapy approaches remain similar for both 
entities (10, 11, 75-77). Despite the benefits of chemotherapy in the palliative setting, 
the prognosis of advanced gastric cancer remains poor (78, 79). 
New therapeutic regimens with acceptable toxicity have been actively pursued, namely 
molecular targeting agents. Several drugs are objects of current interest, such as 
bevacizumab, cetuximab, erlotinib and sorafenib. In this context, bevacizumab (a 
monoclonal antibody against VEGF-A) added to docetaxel + cisplatin + 5-FU showed a 
median OS of 16.2 months and 6-month PFS of 79% in metastatic gastroesophageal 
adenocarcinoma (80). With bevacizumab added to a regimen of  docetaxel + cisplatin + 
irinotecan, a partial response in 63% and stable disease in 30% of patients was 
achieved (81). Cetuximab, a recombinant monoclonal antibody, binds to the 
extracellular domain of the human EGFR, competitively inhibiting the binding of 
epidermal growth factor and other ligands. In pre-treated patients, cetuximab shows 
poor response rates, in the order of 6% (82). Better results have been observed in the 
first line metastatic setting combining cetuximab with various chemotherapy regimens, 
yielding response rates between 41% and 69% and median OS between 9.0 and 16.6 
months (79). Erlotinib is a small molecule TKI that inhibits EGFR autophosphorilation 
and therefore downstream signal transduction (79). In a phase II trial of erlotinib in GEJ 
junction and gastric adenocarcinomas, an overall response probability of 9% was 
estimated, all of them occurring in GEJ cancer patients. Median survival was 6.7 
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months in GEJ and 3.5 months in gastric cancer. Interestingly, no somatic mutations of 
the EGFR exons 18, 19, or 21 or amplification of EGFR were detected. The authors 
concluded that erlotinib showed activity in GEJ adenocarcinoma, but appeared inactive 
in gastric cancer (83). Sorafenib is a multi-target TKI, against RAFK, PDGFR-β, VEGF-
2 and VEGFR-3. In a phase II trial by the SWOG, 53 patients with metastatic or locally 
advanced unresectable disease were treated with sorafenib + docetaxel + cisplatin. 
Median OS was 14.9 months with a median PFS of 5.8 months (84).  
 
HER2 as a therapeutic target 
The importance of addressing HER2 as a therapeutic target is underscored by a 
number of molecular and pathological findings. Upregulated HER2 level causes 
tumorigenesis and the level of HER2 gene expression is much higher in cancer cells 
than that in non-malignant adult cells. HER2 overexpression is found in both primary 
tumours and metastasized organs. (85) Furthermore, HER2 is the preferred 
dimerization partner for other HER receptors in the activation of HER signaling 
pathways, and the HER2 containing heterodimers have the highest mitogenic potential 
among all HER complexes. (35) HER2 overexpression has been reported in breast, 
lung, salivary gland, ovary, colon, prostate and pancreatic cancers. (86)  
About 10–34% of invasive breast cancers present HER2 overexpression, which stands 
as a poor prognosis marker for chemo- and endocrine therapy but at the same time as 
a positive predictive marker for treatment with trastuzumab, which has shown survival 
advantage in early and metastatic disease and is a part of standard care. (87). 
Trastuzumab proved to be effective as adjuvant treatment in breast cancer with HER2 
overexpression, with various chemotherapy regimens (88-94). In the adjuvant setting, 
the HERA trial showed that trastuzumab treatment for one year after chemotherapy 
correlates with improved status at four-year follow up and improved outcome (95). 
Neoadjuvant chemotherapy is increasingly becoming standard for patients with 
inflammatory or locally advanced breast cancer, being currently increasingly used in 
patients with operable disease (96). In the 2010 NOAH phase III trial, the addition of 
trastuzumab to anthracycline and taxane-based chemotherapy was assessed in two 
arms of HER2-positive patients with locally advanced and inflammatory breast cancer. 
The complete pathological response was higher in the trastuzumab-treated arm than in 
the standard arm (87% vs. 74%) (97). The GeparQuattro phase III trial  showed a 
better complete pathological response in the trastuzumab arm when compared with the 
standard chemotherapy arm 31.7% vs. 15.7% respectively (98). 
In metastatic breast cancer, a therapeutic role for trastuzumab is also established, 
particularly in combination regimens. In a phase I study by Nakayama et al., the 
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association of S-1 and trastuzumab attained overall response and disease control rates 
of 33.3 and 83.3% respectively (99). Morrow et al. evaluated the combination of 
trastuzu-mab and everolimus (a mTOR inhibitor), in HER2-positive metastatic breast 
cancer. This association showed good performance in patients who had previously 
been treated with a trastuzumab-based regimen, with a clinical benefit rate of 34%, a 
partial response in 15% of patients and a stable disease rate of 19% (100). 
In the particular case of breast cancer, recognition of the molecular signature of HER2 
overexpression / HER2 amplification using immunohistochemistry (IHC) or in situ 
hybridization (ISH) is widely used to tailor therapeutic regimens involving trastuzumab. 
Clinical application of HER2 targeted therapy 
Prognostic significance 
The most important prognostic factor for gastric cancer is the TNM stage which 
evaluates depth of invasion, involvement of lymph nodes and distant metastasis (64, 
88). HER2 overexpression/amplification is currently demonstrated to occur in about 7-
34% of gastric and GEJ cancers, with considerable variation regarding the assay used.  
However, the correlation between the expression of HER2 protein and the prognosis of 
gastric cancer is still controversial. (101-103)  
Initial works addressing the prognostic significance of HER2 amplification reported a 
negative effect on OS and a role as marker of poor short term prognosis began to 
emerge (57, 104). However, conflicting results regarding the prognostic value of HER2 
have been published in the last twenty years. While some studies found a negative 
effect of HER2 on prognosis with reduction in OS (30, 88, 104-111), others found no 
relationship (112-115) and a trend towards improved survival was found in one cohort 
(116). A recent systematic analysis by Jørgensen et al. found that the majority of 
publications (71%) that fulfilled the selection criteria for the analysis, associated HER2-
positive status with poor survival and clinicopathological characteristics such as serosal 
invasion, lymph node metastases, disease stage or distant metastases (117). Chua 
and Merrett recently reviewed 49 studies with data regarding the relation of HER2 with 
clinicopathological variables and survival and concluded that HER2 overexpression is 
associated with poorer survival; results pertaining other variables were not conclusive 
(118). Furthermore, HER2 overexpression has been suggested as a molecular 
abnormality in the development of intestinal type gastric cancer and HER2 expression 
increases with disease progression in some studies, leading to the suggestion that the 
initial timing of this event probably occurs in early stages. Barros-Silva et al. found 
overexpression and amplification in both components of mixed tumours (with intestinal 
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and diffuse types) and HER2 amplification in early stages, supporting the idea of 
amplification in an early stage of carcinogenesis (88). This idea is further supported by 
the high levels of concordance between primary tumours and paired metastatic sites 
found by some authors, suggesting HER2 amplification as an early event and not 
acquired at a later moment by cells with metastatic potential (119). Kataoka et al. on 
the other hand found no HER2 positivity in the diffuse component of mixed type cases, 
but also found HER2 overexpression in early TNM T1a cases, pointing towards an 
early event (105, 120, 121). Although these data tend to establish HER2 as a potential 
negative prognostic factor in gastric cancer, the relation seems not to be as consistent 
as in breast cancer (117). In fact, recent studies demonstrate no significant prognostic 
effect. In a study involving 381 metastatic gastric/GEJ cancer patients, Yanjigian et al. 
found that patients with HER2-positive gastric cancer had longer median OS compared 
with HER2-negative gastric cancer patients, but on multivariate analysis HER2 status 
was not an independent prognostic factor (122). Okines et al. analysed the prognostic 
role of HER2 in the MAGIC trial (see above), concluding that HER2 status is not an 
independent prognostic factor in early esophagogastric adenocarcinoma (123). 
Terashima et al. found no correlation with OS in 829 stage II/III resected gastric cancer 
patients (124). Hsu et al. investigated 1036 gastric cancer patients undergoing 
curative-intent resection. Although HER2 positivity emerged as a favourable prognostic 
factor for stage III-IV gastric cancer on univariate analysis, it failed to do so on 
multivariate adjustment (125). 
Despite these conflicting results, it seems likely that HER2 is not associated with an 
adverse prognosis in gastric and GEJ cancer in an extent similar to breast cancer; 
nevertheless, inhibition of the HER2 pathway in patients with HER2 amplification 
demonstrated clinical benefits, as will be discussed in the following section. 
Preclinical data 
Overexpression of HER2 in gastric cancer cells was first related in 1986 by Sakai et al. 
and Fukushige et al. (126, 127). Preclinical models of gastric cancer were successful in 
proving the inhibitory effect of trastuzumab on human gastric cancer cell lines in vitro 
and in mice xenografts in vivo, with additive and synergistic antineoplasic effects in 
combination with chemotherapy (128-132). A study by Tanner et al. points out a gastric 
cancer cell line that was as sensitive to trastuzumab as a breast cancer cell line, both 
of them with amplified HER2 (30), while Matsui et al. reported suppression of tumor 
growth in a xenograft model (130). Enhanced antineoplasic effects were observed with 
capecitabine, cisplatin, docetaxel, paclitaxel and irinotecan (128), and a further 
synergistic effect with cisplatin has been found by Kim et al. (131). 
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Clinical data 
As noted earlier, although information on the specific pathways involved is scarce, 
HER2 has been shown to be amplified in gastric cancer and HER2 is progressively 
regarded as an important biomarker and driver of carcinogenesis in gastric cancer, with 
studies pointing out amplification or overexpression in 7-34% of tumours, mainly in the 
intestinal type and in GEJ and proximal tumours (30, 64, 133). The correlation of 
intestinal type histology with HER2 overexpression (75% vs. 9% in diffuse type) may be 
in part explained by E-cadherin mutations (134). In gastric cancer, HER2 gene 
amplification  associates  inversely  with  E-cadherin   mutations, which are far more 
common in diffuse type gastric cancer than in the intestinal type (134). 
The broad variation in numbers concerning amplification/overexpression is due in part 
to a lack of a standardized definition of HER2 positivity in gastric cancer, histological 
variation within gastric cancer tissues, different scoring systems and laboratorial 
methods. Taking into account the investigational data and clinical experience from 
breast cancer and considering the possible benefits of introducing HER2 targeted 
therapy in gastric cancer, a standardized scoring system was developed and validated 
for the ToGA (Trastuzumab for Gastric Cancer) trial. 
The ToGA trial constitutes a milestone, establishing trastuzumab as the first biological 
therapy that demonstrated survival benefits in gastric cancer exhibiting HER2 
expression (128, 130). ToGA was a multicenter, international trial, undertaken in 24 
countries (101). It evaluated the combination of trastuzumab with standard 
chemotherapy (cisplatin + either capecitabine or 5-FU) in advanced (inoperable locally 
advanced, recurrent or metastatic) HER2-positive gastric and GEJ cancer as a ﬁrst-line 
therapy vs. chemotherapy alone. Patients were treated with six cycles of chemotherapy 
in both treatment arms, with patients in the experimental arm continuing to be treated 
with trastuzumab until disease progression. Cisplatin 80 mg/m² was given on day 1 by 
intravenous infusion. Capecitabine 1000 mg/m² was given orally twice a day for 2 
weeks followed by a 1-week rest or 5-FU 800 mg/m² per day was given by continuous 
infusion on days 1–5 of each cycle. Trastuzumab was given intravenously at a loading 
dose of 8 mg/kg on day 1 of the ﬁrst cycle, followed by 6 mg/kg afterwards. 
The primary objective of the study was to compare OS in both arms, and the secondary 
objectives were to compare PFS, time to progression, overall response rate, disease 
control, duration of response and quality of life between the two treatment arms. 
Among 3665 tumor tissue specimens screened for HER2 positivity, 22% were HER2 
positive (34% of the intestinal type vs. 6% of diffuse and 20% of mixed types). 
Assessment was done with IHC and fluorescence ISH (FISH), according to Fig. 4.  
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Figure 4 
HER2 assesment in the TOGA trial 
 
The highest rate was observed in 34% of GEJ cancer and 20% of gastric cancer 
samples, (135) which is in conformity with other studies where positivity rates for the 
GEJ are between 24-35% and in gastric cancer samples comprise 9.5-21%. (12, 30, 
64, 136, 137)  
The combination of trastuzumab with chemotherapy in advanced HER2-positive cancer 
patients led to signiﬁcantly better OS compared to the same chemo-therapeutic 
regimen alone (median OS in the combination therapy group was 13.8 months against 
11.1 months in the chemotherapy-alone group). This effect was observed in patients 
with intestinal type gastric cancer but not in those with diffuse type gastric cancer. (26, 
101) Median PFS (6.7 vs. 5.5 months) and radiological response rate (47% vs. 35%,) 
also improved with trastuzumab therapy. Exploring these data further, a sub-group 
analysis of the ToGA study which excluded patients with IHC 0-1+ FISH+ disease, 
found a main gain in medial survival of 4.2 months, comparable to the figures in breast 
cancer (57). In fact, patients with strongest HER2 expression (IHC 3 + FISH +) gained 
the greatest benefit, with a median survival of 17.9 months in patients treated with 
trastuzumab vs. 12.3 months with chemotherapy alone. A summary of selected clinical 
trials of trastuzumab in gastro-esophagic cancer can be found in table 1. 
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Reference Phase Treatment n OS 
(mo) 
PFS 
(mo) 
%RR %CR %PR 
Bang et al. (101) 
 
III 5FU + cisplatin or 
capecitabine + 
cisplatin 
290 11.1 5.5 34.5 N/A N/A 
Trastuzumab + 
5FU + cisplatin or 
trastuzumab + 
capecitabine + 
cisplatin 
294 13.8 6.7 47.3 N/A N/A 
Cortés-Funes et 
al. (138) 
II Trastuzumab + 
cisplatin 
21 N/A N/A 41.1 5.8 35 
Egamberdiev et 
al. (139) 
II Trastuzumab + 
leucovirin + 
cisplatin + 5FU 
16 N/A 8.3 54.5 N/A N/A 
Leucovirin + + 
cisplatin + 5FU 
18 N/A 5.2 33.3 N/A N/A 
Gravalos et al. 
(140) 
II Trastuzumab + 
cisplatin 
22 N/A 5.1 32 N/A N/A 
Table 1 
Trials of trastuzumab in gastro-esophagic cancer 
Abbreviations: RR, response rate; CR, complete response; PR, partial response; N/A, 
not available. 
 
In 2007, Cortés-Funes et al. presented preliminary results of a phase II study involving 
21 chemothreapy-naïve patients with HER2 overexpressing locally advanced or 
metastatic gastric cancer. Trastuzumab at a loading dose of 8 mg/kg and maintenance 
dose of 6 mg/kg and cisplatin 75 mg/m2 were administered every 21 days until 
progression, unacceptable toxicity or withdrawal of consent. Response rate was of 
35%, with 17% of patients achieving stabilization. The tolerability profile was 
favourable; no grade 4 toxicity was observed and most the frequent grade 3 events 
were asthenia, nausea or vomiting, diarrhea, hiporexia and neutropenia (138). Data 
from another preliminary phase II study involving 16 gastric cancer patients were 
presented by Egamberdiev et al. in 2011. Trastuzumab 6mg/kg was administered once 
in addition to cisplatin 100 mg/m2 during 3 days + 5-FU 1000 mg/m2 3 days + leucovirin 
100 mg/m2 3 days, every 3 weeks. Authors reported an objective response rate of 
54.5% in the combined therapy group vs. 33.3% in the chemotherapy-only group and a 
median remission duration of 8.3 vs. 5.2 months (139). In a recent phase II study 
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carried out by Gravalos et al., chemo-naïve patients with non-resectable advanced or 
metastatic gastric or GEJ adenocarcinoma overexpressing HER2 were treated with 
trastuzumab 8 mg/kg as loading dose and 6 mg/kg in subsequent cycles + cisplatin 75 
mg/m2 every 3 weeks. Twenty-two out of 228 patients (9,6%) enrolled had HER2 
overexpression. An overall response rate of 32% was found, with disease control 
achieved in 64% of patients; median time to progression was 5.1 months. No grade 4 
toxicities occurred, whereas most frequent grade 3 adverse events were asthenia, 
neutropenia, anorexia, diarrhoea and abdominal pain. Interestingly, higher baseline 
HER2 extracellular domain levels associated with better response to therapy (140).   
In more recent studies, HER2 overexpression was found to be lower than previously 
reported, especially in distant gastric cancers (141). Resectable gastric cancer has 
reported HER2-positive ratios of 8.1% and 11.7%, suggesting that in resectable gastric 
cancer HER2 positive status might be less frequent than in advanced gastric cancer 
(142, 143). In this behalf, it is important to consider the possible benefits of 
trastuzumab in the adjuvant setting for earlier stages of the disease; however activity of 
targeted therapeutics in advanced disease should not automatically be extrapolated 
into the adjuvant setting, as results may be misleading (27). Trials have been initiated 
which intend to investigate anti-HER2 therapeutics in this setting (144, 145). Early 
onset gastric cancer (presenting at or under the age of 45) seems to have lower HER2 
overexpression than in late onset cases, with possible different molecular genetic 
pathways (146-148).  
Anti-HER2 agents 
Trastuzumab 
Trastuzumab is a fully humanized monoclonal antibody that binds to the extracellular 
domain of the receptor and acts by blockage of HER2 receptor cleavage and inhibiting  
dimerization, as well as by the induction of antibody-dependent cellular cytotoxicity 
(ADCC), increasing endocytosis of the receptor and possibly through anti-angiogenic 
effects (149-151). It was developed in the 1990s, after murine monoclonal antibodies 
directed to the extracellular domain of HER2 were produced and evaluated in cell lines 
and xenografts (129, 152, 153).  
In January 2010, based on ToGA trial results as previously discussed, the European 
Medicines Agency (EMA) granted approval to trastuzumab plus chemotherapy in the 
treatment of with IHC 3+ or 2+/metastatic adenocarcinoma of the stomach or GEJ 
(154). The U.S. Food and Drug Administration (FDA) approved trastuzumab for HER2 
overexpressing patients, without further specification (155). 
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Pharmacokinetics and pharmacodynamics 
Most data regarding the pharmacokinetic and pharmacodynamic profiles of 
trastuzumab stem from studies in breast cancer. A low systemic clearance (5.15 ± 2.45 
mL/kg/day) and volume of distribution (44 mL/kg) have been described. Serum 
minimum concentrations of 10 µg/mL are needed to attain anti-proliferative effects and 
ADCC. With the usual loading dose of 4 mg/kg followed by 2 mg/kg/week, trastuzumab 
achieves and maintains serum minimum concentrations greater than 20 µg/mL. Recent 
results demonstrate that trastuzumab 6 mg/kg every 3 weeks lead to the same plasma 
trough levels as trastuzumab 2 mg/kg weekly. Trastuzumab has been found not to 
exhibit dose-related nonlinear pharmacokinetics and the value of half-life of 
trastuzumab has an estimated value of 28.5 days (156, 157). No relevant drug 
interactions have been reported to date and elimination pathways remain largely 
unknown (158). Targeted delivery systems involving anti-HER2 antibody mediated 
nano-scaled systems, drug conjugates, and fusion proteins are under active 
investigation (35, 159, 160). 
Safety 
The  most  commonly described adverse  events  with  trastuzumab are infusion-
related, described as fever, rigors, chills, nausea, dyspnea, and hypotension, and are 
present in about 40% of patients after the first administration and in 5% with 
subsequent treatment (78). Trastuzumab has been extensively evaluated in breast 
cancer with a wide range of chemotherapeutic agents showing no signiﬁcant 
overlapping toxicity, with one important exception, regarding an increased risk of 
cardiotoxicity. Trastuzumab-related cardiac dysfunction is largely reversible on 
withdrawal of the antibody. However, significant cardiopathy such as valvular heart 
disease, angina pectoris, previous transmiocardial infarction and heart failure with left 
ventricular ejection fraction (LVEF) ≤ 50% or a drop > 10% from baseline LVEF are 
generally regarded as counter-indications for trastuzumab use (57). With the 
chemotherapy doublet regimen evaluated in the ToGA trial, trastuzumab contributed 
with little added toxicity; no increase in chemotherapy related grade 3–4 toxicities (68% 
both arms) or cardiac events (6% both arms) were found. Nonetheless the number of 
patients with cardiac dysfunction (considered a ≥10% drop in LVEF to an absolute 
value <50%) was low in both arms (5% trastuzumab + chemotherapy vs. 1% 
chemotherapy alone). The European Society for Medical Oncology (ESMO) (161), 
issued a statement regarding the cardiac monitoring of patients receiving trastuzumab. 
Clinical evaluation and assessment of cardiovascular risk factors and comorbidities 
should be performed in every patient proposed for treatment with trastuzumab (162). 
Michael Sapateiro Luís 2013  24 
While screening algorithms for trastuzumab-induced cardiomyopathy provide guidance, 
patient–based strategies of surveillance remain important. Many clinical trials involving 
patients with metastatic breast cancer include a screening study to document the 
baseline LVEF, followed by serial monitoring at 8-to-16-week intervals (163). 
In the ToGA trial, serious adverse events were reported in 32% of patients treated with 
trastuzumab + chemotherapy and 28% in the chemotherapy group; with treatment-
related mortality of 3% and 1% respectively. The adverse events were similar between 
both groups, with no difference in the overall rate of adverse events. Nausea, 
neutropenia, vomiting, and anorexia were the most frequently reported adverse events. 
Patients treated with trastuzumab + chemotherapy had slightly higher rates of 
diarrhoea, stomatitis, anemia, thrombocytopenia, fatigue, chills, weight loss, pyrexia, 
mucosal inﬂammation, and nasopharyngitis (101). In a phase II study with trastuzumab 
and cisplatin as first-line therapy in GEJ and gastric cancer, trastuzumab showed a 
favourable toxicity profile (140).  
Resistance to trastuzumab 
Whilst data regarding mechanisms of resistance to trastuzumab in gastroesophageal 
cancer is scarce, important information can be retrieved from previous knowledge in 
the treatment of breast cancer. Primary resistance to single-agent trastuzumab in 
HER2-overexpressing metastatic breast carcinomas is described in 66 - 88% of cases, 
with resistance eventually ensuing after a relatively short treatment period; in fact, the 
majority of patients who achieve an initial response to trastuzumab-based regimens 
develop resistance within 1 year (PFS between 6.7 and 7.4 months)  (134, 164-166).  
Proposed resistance mechanisms include aberrations in the PI3K/AKT/mTOR pathway 
with or without loss of the PTEN (phosphatase and tensin homologue protein) tumor 
suppressor gene, accumulation of truncated forms of the HER2 receptor that lack the 
extracellular trastuzumab-binding domain (collectively known as p95HER2), loss of 
phosphatase, activation of other tyrosine kinase receptors including the insulin-like 
growth factor receptor (IGF-1R), increased expression of membrane-associated 
glycoprotein (MUC4) and cyclin E overexpression (96, 134, 166). 
PTEN inhibits PI3K, thereby inhibiting the PI3K/AKT/mTOR pathway. Loss of this tumor 
suppressor gene leads to at least partial resistance to trastuzumab. Indeed, both PIK3 
mutations and PTEN loss were associated with inferior PFS and OS in a retrospective 
study of 256 HER2-positive metastatic breast cancer patients treated with trastuzumab 
(167). A potential role for PI3K, AKT or mTOR inhibitors seems to exist, since these 
agents preclude the constitutive activation of this pathway, reversing PTEN loss-
induced trastuzumab resistance (100, 168-170).  
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Truncated forms of HER2 which arise through the proteolytic shedding of the 
extracellular domain of full-length HER2 or by alternative translation initiation from two 
methionine residues are the predominant HER2 forms in some tumours. The biological 
function of p95HER2 has not been fully characterized, though overexpression of 
p95HER2 has been shown to lead to growth of tumor xenografts in nude mice. The 
p95HER2 protein has kinase activity, and this activity is required for tumor growth; 
however, the mechanisms involved and its possible relationship with those used by full-
length HER2 are still unknown. Importantly, since p95HER2 lacks the binding site for 
trastuzumab, it conveys resistance to this antiboby. p95HER2 is ex-pressed in 
approximately 30% of HER2-positive breast tumours and is correlated with poor 
disease-free survival (DFS) and increased nodal metastasis when compared with 
patients that express full-length HER2 (96, 171). p95HER2 can therefore be seen as a 
prognostic and predictive biomarker in breast cancer. In one study analysing 93 
metastatic breast tumors, patients overexpressing p95HER2 were found to have a 
higher incidence of lung metastases and had significantly shorter PFS and OS with 
trastuzumab treatment in comparison with patients expressing only the full-length 
receptor (172).  
Tumors that express p95HER2 may be resistant to trastuzumab but sensitive to the 
inhibitory effects of lapatinib, a low-molecular-weight dual tyrosine kinase inhibitor (TKI) 
of HER1/2 that has activity in patients with HER2-expressing tumors that are resistant 
to trastuzumab. Combination of trastuzumab with lapatinib has been evaluated in 
women with HER2-positive, trastuzumab-refractory metastatic breast cancer. Lapatinib 
with trastuzumab was superior to lapatinib alone in clinical benefit: complete response, 
partial response, and stable disease for ≥ 24 weeks was observed in 24.7% of patients 
in the combination arm vs. 12.4% in the monotherapy arm (173, 174). According to 
some authors this combination could provide a chemotherapy-free option after first line 
chemotherapy + trastuzumab (166).   
Increased signalling through other receptor TKIs including EGFR, HER3, MET and 
IGF-1R has been found in cells resistant to HER2-targeting treatments (166). 
PI3K/AKT/mTOR pathway activation through upregulation of HER3 signalling was 
demonstrated after exposure of breast cancer cells to HER TKIs (175). On the other 
hand, pertuzumab, a HER2-HER3 dimerization inhibitor has demonstrated activity 
against trastuzumab resistant breast cancer cells (176). Taking this findings into 
account, HER3 seems to play an important role in the mechanism of trastuzumab 
resistance. 
In preclinical studies, co-expression of HER2 and IGF-1R in breast cancer cells 
resulted in loss of sensitivity to trastuzumab, conversely, inhibiting ligand-mediated 
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activation of IGF-1R restored sensitivity to trastuzumab, therefore pointing towards a 
possible strategy to reduce or delay trastuzumab resistance (177, 178).  
Overcoming resistance to trastuzumab 
Strategies to overcome trastuzumab resistance imply the important fact that many 
HER2-positive gastric tumours retain dependency on downstream signalling via the 
HER2 pathway. Therefore, besides other anti-HER2 agents (described in the following 
section), a focus on targeting these downstream signalling molecules has emerged 
(179, 180). Implied targets include mTOR inhibitors, HSP90 inhibitors and MET 
inhibitors; particularly interesting data exists concerning the possibility to combine 
some of these agents with anti-HER2 agents on which a patient has progressed, as the 
potential to reverse resistance to trastuzumab has been demonstrated (181-183).  
Adjuvant treatment 
In this behalf, it is important to consider the possible benefits of trastuzumab in the 
adjuvant setting for earlier stages of the disease; however activity of targeted 
therapeutics in advanced disease should not automatically be extrapolated into the 
adjuvant setting, as results may be misleading (27). Trials have been initiated which 
intend to investigate anti-HER2 therapeutics in this setting (144, 145). Early onset 
gastric cancer (presenting at or under the age of 45) seems to have lower HER2 
overexpression than in late onset cases, with possible different molecular genetic 
pathways (146-148). 
Maintenance therapy 
From a clinical perspective, data known from breast cancer suggest that trastuzumab 
administration after disease progression might have benefits in OS (91, 134). In an 
observational of study of 623 patients, median time to progression was longer in 
patients who continued trastuzumab beyond progression than in those who stopped 
(10.2 vs. 7.1 months) (184). Data from an interventional study involving 156 patients 
revealed OS rates of 20.4 vs. 25.5 months and response rates of 27 vs. 48.1%   in 
patients who stopped and continued trastuzumab beyond progression, respectively. 
Continuation of trastuzumab beyond progression was not associated with increased 
toxicity (185). However, the issue is still a matter of debate, as increasing therapeutic 
options pose a challenge on the best possible sequencing and combinations of these 
interventions (186-188). 
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Perioperative treatment 
Perioperative chemotherapy regimens have shown promising results in gastric cancer. 
The MAGIC trial randomized over 500 patients to either surgery alone or perioperative 
chemotherapy consisting of epirubicin, cisplatin and fluorouracil (3 cycles before and 3 
cycles after surgery). This triplet therapy demonstrated a decrease in tumor size and 
improved PFS and OS in comparison with surgery alone (61, 123). In addition, some 
data indicate that response to neoadjuvant treatment is a major predictive factor of 
survival after curative surgical resection (189). 
Although there is no trial so far reporting results on the role of trastuzumab in the 
neoadjuvant setting, a number of case reports with trastuzumab-containing 
neoadjuvant chemotherapy regimens have been published, with interesting outcomes; 
complete pathological responses were attained in 2 cases and a partial response with 
tumor mass reduction allowing for an extensive surgery in another case  (190-192).  
 
Other anti-HER2 agents 
Lapatinib 
Lapatinib is a dual tyrosine kinase inhibitor (TKI) active on both EGFR and HER2, with 
known activity in trastuzumab resistant advanced breast cancer; data suggests that 
there is no cross-resistance with trastuzumab and lapatinib restored trastuzumab 
sensitivity in preclinical models. (57, 193, 194) Wainberg et al. evaluated the effect of 
lapatinib in HER2-amplified cell lines and xenograft models, concluding that lapatinib 
inhibits the growth of HER2-amplified cancer cell lines, induces cell cycle arrest and 
apoptosis and acts synergistically with trastuzumab (195). 
It is approved as combination therapy with capecitabine for patients with HER2-
overexpressing breast cancer with prior progression on trastuzumab, an anthracycline 
and a taxane (196). In a phase II trial conducted by Galsky et al., patients with HER2 
amplified gastro-esophageal, bladder, ovarian, or uterine tumours were enrolled into a 
double-blinded randomized discontinuation study of lapatinib 1500 mg per os a day. Of 
a total of 141 patients screened, 32 patients with HER2 amplified tumours were 
enrolled in the study. At 3 months, 1 (3%) patient had a complete response (CR), 9 
(28%) had stable disease, 20 (63%) had progressive disease, and 2 (6%) were 
unknown.  
Unfortunately, due to low response rate and slow enrolment, the study had to be closed 
early. Concerning gastro-esophageal cancer, a modest CR rate of 6.25% was reported 
(197). A phase II study with lapatinib as first-line therapy in 47 patients with advanced 
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gastric cancer showed modest single-agent activity, with 12% response rate, 20% 
disease stabilization, 7% of patients experiencing partial response and a median OS of 
5 months, less than that seen with conventional cytotoxic chemotherapy (198). Another 
phase II study of lapatinib monotherapy in patients with HER2-overexpressing GEJ or 
esophageal cancer reported limited single-agent activity, with no objective responses 
and stable disease in 8% of pacients (199). Lapatinib in conjunction with capecitabine 
in the first line treatment of HER2 positive metastatic gastric cancer setting was 
addressed in a multicenter phase II trial, reporting a response rate of 22% and stable 
disease rate of 45% (200).  
In another phase II trial, partial response of 24% and stable disease in 34% of patients 
was reported with lapatinib + capecitabine. Most frequent grade 3 and 4 side effects 
were anorexia, hand-foot syndrome, anemia and nausea; no significant cardiotoxicity 
was reported (201). Two phase III studies evaluating the role of lapatinib in 
combination with chemotherapy in advanced esophagogastric cancer are currently 
being conducted, the LOGIC trial (202, 203) (combination of lapatinib with oxaliplatin 
and capecitabine as first-line treatment) and the TYTAN trial (204, 205) (lapatinib in 
combination with weekly paclitaxel in second-line setting). 
Data from the TYTAN trial were presented at ASCO GI 2013. 430 patients were 
randomized, with an OS of 11 months for the experimental arm vs. 8.9 months for the 
paclitaxel-alone arm; the subgroup of patients with HER2 3+ expression score attained 
an OS of 14 months.  
As previously stated, dual blockade with lapatinib and trastuzumab in metastatic breast 
cancer patients that progressed on trastuzumab-containing regimens improved PFS 
and clinical response rate (174); a clinical case reported durable stable disease in a 
patient treated with this strategy despite progression during prior chemotherapy with 
trastuzumab (206).     
 
Pertuzumab 
Pertuzumab is a monoclonal antibody targeting HER2 in domain II (see Fig. 1), 
preventing formation of the highly mitogenic HER2/HER3 dimer. Available data stem 
mostly from breast cancer. As with trastuzumab, the antibody is not effective in patients 
without amplification of HER2 (207). In the phase III CLEOPATRA study, 808 patients 
with HER2-positive metastatic breast cancer received placebo + trastuzumab + 
docetaxel (control group) or pertuzumab + trastuzumab + docetaxel (pertuzumab 
group). Median PFS was 12.4 months in the control group vs. 18.5 months in the 
pertuzumab group. The hazard ratio for the addition of pertuzumab to docetaxel + 
trastuzumab for PFS was 0.62, with moderate toxicity added by the second antibody 
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(208). Pre-clinical results show potentiation of trastuzumab antitumour activity when 
combined with pertuzumab (209). Pertuzumab is currently under investigation in a 
phase II study, in the first line gastric setting in combination with trastuzumab and 
platinum-fluoropyrimidine based chemotherapy (210). 
 
 
 
T-DM1 
Trastuzumab emtansine (T-DM1) is an antibody-drug conjugate, which combines 
trastuzumab with the targeted delivery of the cytotoxic agent DM1, a derivative of 
maytansine, and a potent antimicrotubule agent. As systemic therapy, gastrointestinal 
toxicity limits the therapeutic usefulness of the agent (166). In xenograft models, T-
DM1 was found more effective than trastuzumab alone, with positive results  
independent of the tumor burden at therapy initiation or preceding treatment with 
trastuzumab (159). In a phase II study by Burris et al., T-DM1 had robust single-agent 
activity in patients with heavily pretreated, HER2-positive metastatic breast cancer, with 
a favourable toxicity profile (211). In breast cancer, the EMILIA trial assigned patients 
with HER2-positive advanced breast cancer, previously treated with trastuzumab and a 
taxane, to T-DM1 or lapatinib + capecitabine. Median PFS was 9.6 months with T-DM1 
versus 6.4 months with lapatinib plus capecitabine; with an objective response rate of 
43.6% for T-DM1 (212). Taken together, results from preclinical studies and in breast 
cancer clinical trials point out T-DM1 as a promising agent to be evaluated in gastric 
cancer. Currently, a phase II-III study is ongoing to evaluate T-DM1 versus taxane in 
patients with previously treated locally advanced or metastatic HER2+ gastric and GEJ 
cancer. (213) 
 
Pan-HER TKIs 
Irreversible small molecule pan-HER TKIs causes tumor regression in HER2-
overexpressing  human  gastric  cancer  xenograft  models. They act by inhibition of 
HER family receptor phosphorylation and blocking of hetero-dimerization among them. 
Pre-clinical data reveal a synergistic effect with other molecular targeted agents 
(including trastuzumab) and chemotherapeutic agents (214). Currently investigated 
pan-HER TKIs include dacomitinib and afatinib. Dacomitinib (PF00299804) is a pan-
HER small molecule inhibitor, with antitumor activity reported in HER2-positive gastric 
cancer cell lines and xenografts, and synergy observed with several commonly used 
cytotoxics (5-FU, cisplatin, docetaxel and paclitaxel), targeted agents such as 
trastuzumab (214).  
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Other HER2-directed strategies 
HER2 vaccines, both DNA and peptide-based, are actively researched in the field of 
breast cancer and results indicate a possible future role for this modality in combination 
with other HER2 targeted therapies. A phase I study carried out by Hamilton et al. 
combined HER2 immunization with lapatinib found this combination to be safe and 
immunogenic, however, the anticancer activity of immunization-induced antibodies is 
still not well characterized (215). Successful repression of the HER2 gene by the 
means of adenovirus constructs rises expectations for possible applications in cancer 
treatment (216). Radioimmunotherapy is another possible application of HER2 directed 
homing, namely 212Pb conjugated with trastuzumab in intraperitoneal cancer showed 
interesting results (217, 218). 
 
HER2 testing in gastric cancer 
As mentioned before, HER2 overexpression is currently estimated to occur in about 7-
34% of gastric and GEJ cancers as a whole, with considerable variation regarding the 
assay used (101-103). There is some controversy about the concordance between 
HER2 overexpression and HER2 amplification in gastric cancer. In breast cancer, 
standardized methods of FISH and IHC assessments have been developed, with 
concordance rates between the two methods around 73-98%, and overexpression is 
regarded as achieved primarily through gene amplification (219, 220). In gastric cancer 
however, earlier studies did not observe high concordance between the two methods 
and overexpression without amplification was described in some studies, with some 
authors postulating possible alternative mechanisms of overexpression by 
transcriptional activation by other genes or post-transcriptional events (64, 221). 
Recent studies report high concordance between overexpression assessed by IHC and 
amplification by FISH or chromogenic ISH (CISH), with both surgical resected material 
and biopsy specimens suitable for evaluating gastric cancer for HER2 status (222). 
Tsapralis et al. recently concluded that in gastric cancer HER2 amplification is the main 
mechanism of HER2 overexpression, as happens in breast cancer (223). 
It is important to stress the recent development of validated methods in identifying 
suitable patients for trastuzumab therapy, which differ from the methods used in breast 
cancer (16, 36, 224, 225). Testing of HER2 status by IHC differs from breast cancer in 
fundamental aspects: the IHC 2+/3+ score is attributed even though membranous 
staining is incomplete if membrane staining is clearly detectable even at low 
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magnification or medium magnification; membrane staining at the appropriate intensity 
found in at least 10% of tumor cells is restricted to resection specimens (see table 2).  
 
 
 
 
 
 
 
Score Surgical specimen – staining 
pattern 
Biopsy specimen – 
staining pattern 
HER2 
overexpression 
assessment 
0 No reactivity or membranous  
reactivity in <10% of tumour cells 
No reactivity or no 
membranous reactivity  
in any tumour cell 
Negative 
1+ Faint or barely perceptible  
membranous reactivity in ≥10% of  
tumour cells; cells are reactive only in  
part of their membrane 
Tumour cell cluster with a 
faint or barely  
perceptible membranous 
reactivity  
irrespective of percentage of 
tumour cells  
stained 
Negative 
2+ Weak to moderate complete,  
basolateral or lateral membranous  
reactivity in ≥10% of tumour cells 
Tumour cell cluster with a 
weak to  
moderate complete, 
basolateral or lateral  
membranous reactivity 
irrespective of  
percentage of tumour cells 
stained 
Equivocal 
3+ Strong complete, basolateral or lateral  
membranous reactivity in ≥10% of  
tumour cells 
Tumour cell cluster with a 
strong complete,  
basolateral or lateral 
membranous  
reactivity irrespective of 
percentage of  
tumour cells stained 
Positive 
 
Table 2 
IHC scoring for HER2 in gastric and GEJ cancer, adapted from ref. (101) 
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Evaluation of HER2 amplification by in situ hybridization is similar to breast cancer with 
HER2 / CEP17 ratio (HER2 gene copy number per tumor cell to the chromosome 17 
copy number) values ≥2.0 indicating HER2 gene amplification. Using methods 
developed for breast cancer in gastric cancer can yield markedly different results 
according to some authors. Therefore, new scoring criteria have been validated and 
refined during the ToGA (101) trial and are internationally regarded as standard in the 
determination of HER2 positivity (226). 
Some particularities in the laboratorial assessments are still under debate. For 
example, heterogeneity in gastric cancer tissue is higher than in breast cancer (5% vs. 
1.5%), and therefore CISH, by allowing easier morphological examination, may have 
an advantage over FISH (224, 227). This also raises questions about the adequacy of 
biopsy specimens and the number that need to be analysed (228). Concordance 
between IHC HER2 status between biopsies and gastrectomy material was found to be 
74.1% in one study (229). Using CISH, amplification can only be assessed 
semiquantitatively and quantitative polymerase chain reaction (PCR) techniques have 
been proposed as alternative. Multiplex ligation-dependent probe amplification (MLPA) 
has been tested in breast cancer and could be a possible technique in gastric cancer 
also (12). Another important question refers to the differences between HER2 results 
on primary tumours and corresponding metastases. In a study by Bozzeti et al. a high 
concordance between HER2 status on primary tumours and metastases is described, 
suggesting that in gastric cancer HER2 status is maintained in most cases unchanged 
during the metastatic process (119). On the other hand, Kim et al. found discordance in 
HER2 amplification between primary tumours and metastatic lesions and attributed this 
to heterogeneity within primary tumors (230). The debate on hetero- or homogeneity of 
HER2 amplification by its turn raises the question on the feasibility of tissue 
microarrays vs. whole-tissue sections in practice. In a study of 2009 cases, HER2 
positivity was detected in 12.3% of whole-tissue sections and in 17% of tissue 
microarrays (231). Marx et al. described HER2 amplification as being highly 
homogenous (232), while Yang et al. describe intratumoral heterogeneity (233). 
Discussion about the ideal methodology for HER2 testing in gastric cancer is ongoing, 
(234, 235) with many studies evaluating new methods, including dual colour silver ISH 
(SISH) (236). Kim et al. found high concordance between methods in a study where 
HER2 amplification by FISH and real-time PCR and HER2 expression by IHC were 
performed (237). Other studies revealed similar results and CISH and SISH are 
emerging as a reasonable alternative to FISH, with less expensive costs and 
necessary equipment (222, 238). A high concordance was comproved using the latter 
method compared to FISH in breast cancer (96%) (239). Advantages of SISH include 
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the possibility of being realized in automatic processing equipment, the use of a 
conventional clear-field light microscope (as opposed to fluorescence microscopy in 
FISH) and the easy archiving of glass slides with less signal loss compared to other 
ISH methods, contributing to reduction of costs (240).  
The primary objective was to estimate the proportion of patients with gastric cancer or 
GEJ cancer admitted at IPOP eligible for trastuzumab therapy. Secondary objectives 
were the characterization of the study population according to clinicopathological 
variables and to obtain values of OS and PFS.  
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MATERIAL AND METHODS 
 
Type of study 
Quantitative, non-interventional, retrospective cohort study 
 
Inclusion criteria 
The study population consists of patients with diagnosed gastric or GEJ cancer 
admitted at IPOP from 01.01.2005 to 31.12.2006, as retrieved from the centre 
database. The following selection criteria are applied: 
 Patients with stage IV (according to AJCC 7th Edition) and locally advanced 
disease are selectable, with locally advanced disease being defined as 
T4NxM0, T3NxM0, T2N+M0 or T1N+M0 
 Patients without clearly defined date of first observation, without available 
tumour samples in the institutional archive or lacking variables essential for the 
clinicopathological characterization described below are excluded 
In a first step, this population is characterized according to clinicopathological variables 
such as age, gender, treatment, TNM stage, survival and N-ratio. A second step 
involves the selection of cases potentially eligible for trastuzumab treatment according 
to EMA approval (metastatic, i.e. stage IV adenocarcinoma of the stomach or GEJ) and 
locally advanced disease. In a third step, cases of this latter group are analyzed for 
HER2 overexpression/amplification according to the methods used in the ToGA trial. 
Tumour sample inclusion criteria 
Tumour samples fulfil the following criteria: 
 Histologically confirmed gastric or GEJ adenocarcinoma of the intestinal 
type; 
 Surgical specimens or biopsy specimens with sufficient invasive tumour 
tissue for HER2 overexpression assessment and 
 Specimens must be available at the Department of Pathology of IPOP. 
 
HER2 status testing 
HER2 testing is applied according to the methods described in the ToGA trial (Fig 5). 
(16, 36, 101, 226) 
 
Immunohistochemistry 
IHC targeting the HER2 protein was carried out in 3µm thick tissue sections, on 
adhesive glass slides (Super  Frost  Plus  Menzel®), using a Ventana®  Benchmark  
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ULTRA (Ventana Medical Systems®, S.A. Illkirch, France) automatized equipment. 
The Her2/neu TesT (4B5) antibody and the DAB Ultraview Universal detection kit, both 
by Ventana Medical Systems® were used. 
 
Silver in-situ hybridization  
SISH was processed using the mentioned Ventana® Benchmark ULTRA system, with 
the following kits: Ultraview SISH DNP detection kit, Ultraview RED ISH DIG detection 
kit and Inform Her2 Dual ISH DNA probe cocktail. 
 
Pathological evaluation 
The glass slides used for HER2-status analysis were prepared by Ana Sousa Tavares, 
Pathology Technician and afterwards selected by Pathologist Dr. Luís Pedro Afonso, 
both working at IPOP. The slides were processed by Dr. Dina Leitão at Instituto de 
Patologia e Imunologia Molecular da Universidade do Porto (IPATIMUP). Pathological 
evaluation was performed by Professor Fernando Schmitt. 
 
Figure 5 
 HER2 testing algorithm, adapted from ref. (135) 
 
IHC scoring refers to the criteria outlined in table 1. FISH is considered positive if the 
ratio of the HER2 gene copy number per tumour cell to the chromosome 17 copy 
number (HER2 / CEP17 ratio) is ≥ 2.   
 
Statistical analysis 
Categorical data was analyzed with the χ2 - test. Survival curves are obtained 
according to the Kaplan-Meier method and the significance of differences between 
survival curves is determined using the log-rank test. Patients without known date of 
death will are censored at the date last known to be alive. Values o p < 0.05 are 
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considered statistically significant. Analysis was performed using the computer 
program IBM® SPSS Statistics for Windows®, Version 20.0 (Armonk, USA). 
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RESULTS 
Histology 
 
 
Image 1 
Hematoxilin-eosin staining of gastrectomy sample, with intestinal-type adenocarcinoma 
(a – 10x, b – 40x amplification) 
 
 
 
Image 2 
IHC for HER2 a – negative (10x), b – 1+ (40x), c – 3+ (10x), d – 3+ (40x) 
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Image 3 
SISH for HER2. Chromosome 17 marked red and the HER2 gene in black, 20 and 40x    
 
Description of the sample 
 General sample 
 
In the years of 2005 and 2006, 720 patients were admitted with a diagnosis of gastric 
cancer. Male patients comprise 60.6% of the sample. Table 3 depicts the proportion of 
the different histophatological types (missing cases in the following tables due to lack of 
clinical information). 
 
Histophatological classification Proportion 
Adenocarcinoma 88.8% 
   Intestinal 42.2% 
   Diffuse 22.2% 
   Mixed 8.3% 
   Mucinous 5.3% 
   NOS 10.6% 
Lymphoma 5.6% 
GIST 1% 
Other 4.6% 
Table 3 
 
 Study sample 
 
According to the selection criteria previously enumerated (MATERIALS AND METHODS), 98 
patients were included. 
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Figure 6 
Selection criteria flow-chart 
 
Male patients constitute 57.1% of the sample. Median age at diagnosis was 66 years 
[35 – 89]. No statistically significant difference was found between genders regarding 
age at diagnosis (p = 0.9). Properties of the study sample can be found in table 4. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Patients admitted with the diagnosis of gastric cancer 
n = 720 
 Stage IV and locally advanced disease 
 Intestinal adenocarcinoma 
n = 146 
 
n = 
 Histologic material present at IPOP 
n = 108 
 Enough available clinical data 
n = 98 
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Gender n / % 
   Male  56 (55.1%) 
   Female 42 (44.9%) 
Age Median 66 years 
Tumour  
   Grade  
      1 6 (6.1%) 
      2 51 (52%) 
      3 34 (34.7%) 
   Stage  
      I 3 (3.1%) 
      II 44 (44.9%) 
      III 37 (37.8%) 
      IV 14 (14.3%) 
   Topography  
      Body (including curvatures) 38 (38.8%) 
      Antrum and pylorus 38 (38.8%) 
      Overlapping 12 (12.2%) 
     GEJ 6 (6.1%) 
     Fundus 2 (2%) 
      Undefined 2 (2%) 
Table 4 
 
 Treatment 
 Surgery 
Primary surgery was realized in 93.4% of patients; intent was curative in 68 (80%) 
cases and palliative in 17 (20%). Lymphadenectomy was reported as D2 in 2/3 of 
surgeries. Extent of resection was classified as R0 in 71.8%, R1 in 10.3% and R2 in 
12.8% of cases, with undetermined extent in 5.1%. Mean N-ratio was 20%. A 
correlation between resection and surgical intent is depicted in table 5. 
 
Surgical intent Resection p 
R0 R1 R2 
Palliative 0 (0%) 5 (35.7%) 9 (64.3%) p < 0.001 
Curative 55 (91.7%) 4 (6.7%) 1 (1.7%) 
Table 5 
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 Chemotherapy 
 
Adjuvant chemotherapy was administered in 6 patients submitted to surgery, while 
palliative chemotherapy following after surgery was administered in 10 patients, with a 
cisplatin/5-FU regimen (cisplatin 100 mg/m2 on day 1 + 5-FU 1000 mg/m2/day during 5 
days, cycles interval 28 days). Primary palliative chemotherapy (without prior surgery) 
was used in 2 patients; with the same regimen described above. Neoadjuvant 
chemotherapy was used in 2 patients, also with a cisplatin/5-FU regimen. 
Table 6 describes the use of adjuvant chemotherapy according to stage, N+, resection, 
node sampling and N+ status. 
 
Factor Adjuvant chemotherapy p 
No Yes 
Stage 
   I 3 (100%) 0 (0%) NS 
   II 44 (100%) 0 (0%) 
   III 31 (83.8%) 6 (16.2%) 
Resection 
   0 54 (96.4%) 2 (3.6%) NS 
   1 6 (75%) 2 (25%) 
   2 8 (80%) 2 (20%) 
N sampling 
   ≥ 15 65 (92.9%) 5 (7.1%) NS 
   < 15 13 (92.9%) 1 (7.1%) 
N+ status    
   N- 27 (100%) 0 (0%) NS 
   N+ 51 (89.5%) 6 (10.5%) 
Table 6 
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Survival analysis - overall survival 
Median OS was 36 months [24-48], 87% at 1 year, 59% at 2 years and 37% at 5 years.  
 
Graph 1 
 
OS by stage 
Stage Median OS (months) 
p < 0.001 
I 88 
II  72 [61-83] (mean) 
III  22 [19-25] 
IV 18 [16-20] 
Table 7 
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Graph 2 
 
OS by age (early-onset gastric cancer)  
Age group n Median OS (months) 
p = 0.081 ≥ 45 86 37 [24-50] 
< 45 (early-onset) 4 13 [6-40] 
Table 8 
 
Graph 3 
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OS by resection  
R n Median OS (months) 
p = 0.011 
0 56 88 [20-156] 
1 8 43 [21-66] 
2 10 20 [18-23] 
Table 9 
 
 
Graph 4 
 
OS by N sampling 
N sampling n Median OS (months) 
p = 0.145 ≥ 15 16 43 [31-55] 
< 15 74 22 [16-28] 
Table 10 
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Graph 5 
 
 
OS by N status 
 
N status Mean OS (months) 
p < 0.001 N - 80 [67-92] 
N + 40 [32-48] 
Table 11 
 
Graph 6 
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OS by histological grade 
Only 7 tumours were classified as G1 and 6 tumours had undetermined histological 
grade. A comparison between grades 2 and 3 shows no statistically significant 
difference in OS. 
  
Histological grade n Median OS (months) 
p = 0.231 2 45 43 [11-75] 
3 32 22 [13-31] 
Table 12 
 
Graph 7 
 
OS by N-ratio (ratio between metastatic and examined lymph nodes) 
N-ratio n Median OS (months) 
p < 0.001 
0 25 81 [70-93] (mean) 
1-9% 11 43 [11-75] 
10-25% 22 28 [19-37] 
>25% 29 19 [15-23] 
Table 13 
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Graph 8 
 
Survival analysis - Disease-free Survival (stages I-III) 
Median DFS was 12 months [8-16], 53% at 1 year, 12% at 2 years. 
 
 
Graph 9 
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DFS by stage 
Only 3 patients with stage I disease were included into the sample. 
Stage n Median DFS (months) 
p = 0.090 II  11 16 [7-25] 
III  21 12 [9-15] 
Table 14 
 
Graph 10 
 
 
DFS by age (early-onset gastric cancer)  
Age group n Median DFS (months) 
p = 0.074 ≥ 45 29 12 [9-16] 
< 45 (early-onset) 3 21 [7-35] 
Table 15 
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Graph 11 
 
DFS by N sampling 
N sampling n Median DFS 
(months) 
p = 0.914 
≥ 15 25 14 [10-18] 
< 15 7 9 [3-15] 
Table 16 
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Graph 12 
 
DFS by N status 
 
N status n Median DFS (months) 
p = 0.673 N - 4 12 [1-23] 
N + 28 12 [8-16] 
Table 17 
 
Graph 13 
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DFS by histological grade 
In the subgroup of stage I-III, only 5 tumours were classified as G1, and 4 tumours had 
undetermined histological grade. A comparison between grades 2 and 3 shows no 
statistically significant difference in OS. 
  
Histological grade n Median DFS 
(months) 
p = 0.331 1 3 18 [6-34] 
2 17 12 [5-19] 
3 12 12 [8-16] 
Table 18 
 
Graph 14 
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HER2 
The following tables describe the sample in terms of HER2-status.  
HER2 by IHQ 
0 1+ 2+ 3+ 
79 (80.6%) 1 (1.0%) 4 (4.1%) 14 (14.3%) 
HER2 by SISH 
- + 
2 2 
HER2 final 
- + 
82 (83.7%) 16 (16.3%) 
Table 19 
 
HER2 Stage 
p = 0.05 
 
I II III IV 
- 3 (3.7%)    42 (51.2%) 29 (35.4%) 8 (9.8%) 
+ 0 (0%) 2 (12.5%) 8 (50%) 6 (37.5%) 
Table 20 
 
 
HER2 N status 
p = 0.006 
 
- + 
- 28 (34.1%) 54 (65.9%) 
+ 0 (0%) 16 (100%) 
Table 21 
 
HER2  M status 
p = 0.016 
 
- + 
- 71 (86.6%) 99 (11%) 
+ 9 (56.2%) 6 (37.5%) 
Table 22 
 
 
 
HER2 n Mean OS (months) 
p = 0.032 - 76 43 [21-65] 
+ 14 19 [17-21] 
Table 23 
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HER2 survival analysis 
 
Graph 15 
 
HER2 Mean DFS (months) 
p = 0.572 - 12 [7-17] 
+ 13 [9-18] 
Table 24 
 
Graph 16 
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DISCUSSION 
 
Assessing HER2-status has become standard practice in managing breast cancer, as 
a reliable predictor of response to biological therapeutics with agents targeting the 
HER2 receptor. Apart from breast cancer, other malignancies were studied for possible 
therapeutic approaches and gastric cancer followed as the second neoplasia with 
approved anti-HER2 treatment. Our main objective was to assess the proportion of 
patients with gastric cancer or GEJ cancer admitted at IPOP eligible for trastuzumab 
therapy, taking the new histopathological classification standards developed in the 
context of the ToGA trial into account. On the other hand, this work incorporates a 
wider project, where the costs of this treatment are determined. Therefore, SISH was 
selected as the technique employed to assess amplification, due to its inherent lower 
cost. 
The composition of the general sample generally follows a distribution similar to that 
discribed in the literature. In our study sample, we wanted to include not only 
metastatic cases but also patients with locally advanced disease, in order to better 
understand in which way these patients differ from the metastatic cases and if there is 
a potential role for the use of adjuvant anti-HER2 therapy in this subgroup. In fact, 
adjuvant treatment with anti-HER2 agents in gastric cancer is currently under 
discussion and investigation (188).   
Primary treatment for gastric cancer remains surgery. In our series, patients that 
underwent surgery with a curative intent attained a R0 ressection in 91.7%. 
Adjuvant and neoadjuvant chemotherapy were not frequently used in our sample, 
which can be explained taking into account the years involved (2005 and 2006), where 
the role of this therapeutic modalities was yet to be clarified further. Nevertheless, data 
reveal a tendency for the use of adjuvant chemotherapy in stage III patients, patients 
with incomplete ressections and positive N status. Survival analysis regarding adjuvant 
chemotherapy is limited by the low number of patients that underwent this treatment. 
Median OS was 36 months. As expected, TNM staging was highly correlated with 
different OS between stages, which confirms TNM staging as the most important 
prognostic factor for gastric cancer. Median survival of 18 months for stage IV is 
superior than expected, possibly reflecting the low number of cases (n=14). There was 
a low number of early-onset gastric cancer (n=4); generally in literature gastric cancer 
diagnosed under 45 is described as making up < 10% of all cases. Data reveal a 
tendency for a worse prognosis in this subgroup of patients, in line with previously 
published findings (148). N status significantly influenced OS, therefore further 
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reinforcing the theoretical advantage of adjuvant therapy in these patients. N-ratio, in 
accordance with previous publications, significantly influenced OS (241). 
Median DFS was 12 months [8-16], 53% at 1 year, 12% at 2 years, in other words, in 
our sample about half the patients reccur at 1 year and most of the remaining reccured 
during the following year. Although not statistically significant, there seems to be a 
tendency confirming the higher odds for early recurrence in stage III vs. stage II 
patients. As opposed to the role in OS, N-status did not influence recurrence in a 
statiscally significant way.  
Global HER2-positivity was 16.3%, which is in accordance with expected values using 
the new scoring methods. In a large series published before the new ToGA criteria and 
with patients from the same centre, positivity rate in intestinal type gastric cancer was 
about half of the reported in this series (88). Our positivity rate fits into the 9.5-21% 
positivity rate found in the literature and described in the introduction. The even higher 
ToGA trial positvity rates are probably due to the higher number of GEJ cancers 
analysed, which were only in number of 6 in this series.  
Analysing HER2-status by stage, it becomes apparent that HER2-positive cases are 
diagnosed at later stages, with none of the stage I patients in our sample showing 
HER2 amplification. Further decomposing these analysis, N-status and M-status are 
independently affected by HER2 status, while T is not (p= 0.51). In our sample, OS 
was negatively affected by HER2-positivity, whereas it had no influence in DFS. The 
high difference in median OS (43 vs. 19 months) certainly suffers from a small sample 
size, however, it seem undeniable that patients with locally advanced disease can 
benefit from anti-HER2 therapy. 
As a retrospective work, this study suffers from its inherent limitations. Time and cost 
restraints imposed selection criteria that deserve a further explanation. While the total 
number of patients admitted at IPO during the 2 years considered in the study totalizes 
720 patients, many had diagnostic biopsy and surgery in other hospitals and were 
referred for a second clinical opinion or in order to realize chemotherapy after primary 
surgical treatment. The number therefore decreased to 108 patients, of which 98 had 
sufficient clinical information accessible in a feasible schedule to be included in the 
study sample.  
Various efforts in detecting potential molecular targets in different cancer cell receptors 
are being undertaken, which may lead to the development of novel agents directed 
against kinases (242, 243). As exciting as the evolution of anti-HER2 therapy in gastric 
cancer may be, strategies to overcome resistance need to be pursued while developing 
new treatment strategies. A better understanding of the HER signalling pathways and a 
deeper knowledge about downstream molecules and other signalling pathways 
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including Wnt/β-catenin and TGF- β/SMAD may contribute to one day achieve 
multitargeted and network-based therapy possible (179, 244). In such a perspective, a 
combination of agents will target different crosstalk pathways and contribute to more 
effective therapies (12).  
 
CONCLUSION 
 
Anti-HER2 therapies have established themselves as valuable partners in the 
therapeutic strategies against breast cancer and are now part of the standard of care in 
gastric and GEJ cancer. Our data suggest an important role for theses agents in the 
adjuvant setting and for locally advanced stages. 
However, some open questions remain, regarding the role of these agents in adjuvant 
therapy, the safety in combination with other chemotherapeutic regimens, the optimal 
duration of treatment and its usage after disease progression. Addressing resistance 
and combination therapy with other targeted agents will certainly pose challenges in 
the future. Further studies in the perioperative and adjuvant settings and in earlier 
disease stages are warranted, hopefully further extending the survival benefits already 
found.
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